Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacologic management of metastatic bone disease.
Schwartz E, Reichert Z, Van Poznak C. Schwartz E, et al. Among authors: reichert z. Bone. 2022 May;158:115735. doi: 10.1016/j.bone.2020.115735. Epub 2020 Nov 7. Bone. 2022. PMID: 33171313 Review.
Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.
Smith DC, Daignault-Newton S, Grivas P, Reichert ZR, Hussain M, Cooney KA, Caram M, Alva A, Jacobson J, Yablon C, Mehra R, Escara-Wilke J, Shelley G, Keller ET. Smith DC, et al. Clin Genitourin Cancer. 2020 Aug;18(4):332-339.e2. doi: 10.1016/j.clgc.2019.10.019. Epub 2020 Mar 7. Clin Genitourin Cancer. 2020. PMID: 32299729 Free PMC article. Clinical Trial.
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
Chung JS, Wang Y, Henderson J, Singhal U, Qiao Y, Zaslavsky AB, Hovelson DH, Spratt DE, Reichert Z, Palapattu GS, Taichman RS, Tomlins SA, Morgan TM. Chung JS, et al. Among authors: reichert z. Neoplasia. 2019 Aug;21(8):802-809. doi: 10.1016/j.neo.2019.06.002. Epub 2019 Jul 2. Neoplasia. 2019. PMID: 31276932 Free PMC article.
De novo neuroendocrine transdifferentiation in primary prostate cancer-a phenotype associated with advanced clinico-pathologic features and aggressive outcome.
Abdulfatah E, Reichert ZR, Davenport MS, Chinnaiyan AM, Dadhania V, Wang X, Mannan R, Kunju LP, Hollenbeck BK, Montgomery JS, Kaffenberger SD, Morgan TM, Alva AS, Palapattu GS, Vaishampayan UN, Alumkal JJ, Spratt DE, Udager AM, Mehra R. Abdulfatah E, et al. Med Oncol. 2021 Feb 14;38(3):26. doi: 10.1007/s12032-021-01473-2. Med Oncol. 2021. PMID: 33586037
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
Gharzai LA, Jiang R, Wallington D, Jones G, Birer S, Jairath N, Jaworski EM, McFarlane MR, Mahal BA, Nguyen PL, Sandler H, Morgan TM, Reichert ZR, Alumkal JJ, Mehra R, Kishan AU, Fizazi K, Halabi S, Schaeffer EM, Feng FY, Elliott D, Dess RT, Jackson WC, Schipper MJ, Spratt DE. Gharzai LA, et al. Lancet Oncol. 2021 Mar;22(3):402-410. doi: 10.1016/S1470-2045(20)30730-0. Lancet Oncol. 2021. PMID: 33662287 Free PMC article.
49 results